Future research could incorporate genomic (e.g., KRAS mutation) and proteomic (e.g., circulating tumor DNA) data to improve the model, and explore the correlations between radiomic features (e.g., texture features, volume features) and KRAS mutations, ctDNA levels, as well as the associations between body composition parameters such as VFI and the expression of cytokines such as IL-6, thereby revealing potential imaging-biomarker relationships. Here, KRAS is linked to neoplasm.